DGAP-News: AiCuris' Licensee MSD Received U.S. FDA Approval of PREVYMIS(TM) (Letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients

Nachricht vom 09.11.2017 (www.4investors.de) -


DGAP-News: AiCuris Anti-infective Cures GmbH / Key word(s): Regulatory Approval

AiCuris' Licensee MSD Received U.S. FDA Approval of PREVYMIS(TM) (Letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients
09.11.2017 / 12:51


The issuer is solely responsible for the content of this announcement.
AiCuris' Licensee MSD Received U.S. FDA Approval of PREVYMISTM (Letermovir)
for Prevention of Cytomegalovirus (CMV) Infection and Disease in
Adult Allogeneic Stem Cell Transplant Patients

First antiviral drug developed from AiCuris' pipeline to receive market approval
 
PREVYMIS is the first new medicine for CMV infection approved in the U.S. in 15 years
 
MSD has worldwide rights for development and commercialization of PREVYMIS
 
AiCuris to receive milestone payments and royalties on sales
 
AiCuris now focused on the further development of its pipeline with drugs against antiviral and antibacterial infections
Wuppertal, Germany, November 09, 2017- AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of drugs against infectious diseases, today announced that MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA), received market approval by the U.S. Food and Drug Administration (FDA) for PREVYMIS (letermovir) once-daily tablets for oral use and injection for intravenous infusion. PREVYMIS is indicated for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).

CMV is a common and potentially serious viral infection in allogeneic HSCT recipients. CMV-seropositive patients who undergo an HSCT are at high risk for CMV reactivation. Any level of CMV infection is associated with increased mortality in HSCT patients. CMV prophylaxis with certain existing antivirals has been associated with drug-specific effects, including myelosuppression and renal toxicity, in HSCT recipients.

PREVYMIS (letermovir) is a novel non-nucleoside CMV inhibitor developed by AiCuris through phase II studies prior to licensing the antiviral medicine to MSD in 2012.

"The approval of PREVYMIS by the FDA is a major milestone for our company and is a validation of our scientific approach and ability to successfully discover and develop innovative therapies that have the potential to truly make a difference in the treatment of patients suffering from infectious diseases," said Dr. Holger Zimmermann, CEO of AiCuris Anti-infective Cures GmbH. "I am proud of the team at AiCuris, which has worked hard and with great commitment and dedication. With a pipeline of candidates in clinical development, including pritelivir, an innovative treatment for HSV infections, and a resistance-breaking antibiotic for Gram-negative bacterial infections, we believe we are well positioned to fight more challenges in treating infectious diseases."

"The approval of PREVYMIS in the U.S. under accelerated review reflects the major medical need for new therapeutic approaches for cytomegalovirus infections," said Prof. Helga Rübsamen-Schaeff, founding CEO and Chair of the Scientific Advisory Board of AiCuris. "When designing this drug, we targeted at a new mode of action with a novel chemical molecule. We are very proud that our work will now help prevent CMV infection and disease in adult seropositive patients undergoing allogeneic hematopoietic stem cell transplantation."

Dr. Thomas Strüngmann, who, together with his brother, Andreas, is the main investor in the Company, said: "The approval of PREVYMIS supports our long-term strategic investment approach, and it is gratifying to see that a project we invested in early on now will be able to positively affect the lives of patients. We congratulate the teams at both AiCuris and MSD on this achievement. We look forward to further successes as AiCuris advances other programs in its pipeline."

Under the terms of the agreement with MSD, AiCuris is eligible for milestone payments as well as royalties on net sales. The FDA approval of PREVYMIS triggers a milestone payment to AiCuris in the amount of 105 million Euros. MSD has indicated that the company plans to launch PREVYMIS in December.
 

Please follow the link to the news release issued today by MSD: http://www.mercknewsroom.com/news-release/corporate-news/.
 

About PREVYMISTM (letermovir)

PREVYMIS is a member of a new class of non-nucleoside CMV inhibitors (3,4 dihydro-quinazolines) and inhibits viral replication by specifically targeting the viral terminase complex. Cross resistance is not likely with existing drugs and PREVYMIS is fully active against viruses with substitutions conferring resistance to CMV DNA polymerase inhibitors. PREVYMIS has no activity against other viruses. Letermovir has been granted orphan designation for the prevention of CMV disease in at-risk populations in the U.S., EU and Japan, and is under accelerated review in the EU and Japan.

Under an agreement signed in 2012, MSD (through a subsidiary) purchased worldwide rights to develop and commercialize letermovir from AiCuris (www.aicuris.com).
 

About CMV infection

CMV is a common virus that infects people of all ages. Many adults in the United States are CMV seropositive, meaning they have CMV antibodies in their blood, indicating a previous exposure to or primary infection with CMV. People with normal immune systems rarely develop CMV symptoms after initial infection, with the virus typically remaining inactive or latent in the body for life. A weakened immune system may give the virus a chance to reactivate, potentially leading to symptomatic disease or a secondary infection due to other pathogens. CMV disease can lead to end-organ damage, including gastrointestinal tract disease, pneumonia or retinitis. Transplant recipients who develop CMV infection post-transplant are at increased risk for transplant failure and death.
 

About AiCuris Anti-infective Cures GmbH

AiCuris was founded in 2006 as a spin-off from Bayer and focuses on the discovery and development of drugs against infectious diseases. The Company's majority investor is SANTO Holding. The Company is developing drugs for the treatment of viruses such as human cytomegalovirus (HCMV), herpes simplex virus (HSV), hepatitis B virus (HBV), and adenoviruses. In the field of antibacterials, AiCuris seeks to develop innovative treatment options for life-threatening, (multidrug)-resistant hospital-treated pathogens.

Contacts:

 
Media Relations
AiCuris Anti-infective Cures GmbH
MC Services AG
Katja Woestenhemke
Anne Hennecke
Friedrich-Ebert-Str. 475/Geb. 302
Kaiser-Friedrich-Ring 5
42117 Wuppertal
40545 Düsseldorf
 
 
Phone +49 202 317 63 0
Phone +49 211 529 252 22
Fax +49 202 317 63 1601
Fax +49 211 529 252 29
Email business@aicuris.com
Email anne.hennecke@mc-services.eu
Web www.aicuris.com
Web www.mc-services.eu












09.11.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de



627317  09.11.2017 





Pfeilbuttonmic AG: „Wir wollen Industrie 4.0 und Blockchain verbinden“ - Exklusiv-Interview
PfeilbuttonAURELIUS: „2017 wird das beste Jahr in unserer Unternehmensgeschichte” - Exklusiv-Interview
PfeilbuttonHanseYachts: „Unser Verkaufsapparat läuft inzwischen wie eine geölte Maschine“ - Exklusiv-Interview


+++ Exklusive Interviews und Analysen - gratis in Ihre Mailbox! +++

Tragen Sie sich jetzt für unseren kostenlosen 4investors Newsletter ein.


Bestätigungslink nicht per Mail bekommen? Bitte kontrollieren Sie Ihren Spamordner!

Der 4investors Newsletter erscheint unregelmäßig, i.d.R. 2 bis 6 Mal pro Monat. Wir geben ihre Mailadresse an keinen Dritten weiter! Sie können den kostenlosen 4investors Newsletter jederzeit problemlos wieder abbestellen.
comments powered by Disqus


Aktuelle Nachrichten aus der 4investors-Redaktion

19.11.2017 - Volkswagen will 22 Milliarden Euro investieren - Elektromobilität im Fokus
19.11.2017 - Evotec Aktie: Wichtige Infos für die nächsten Tage
17.11.2017 - tick Trading Software kündigt Dividende an
17.11.2017 - mybet Holding will Wandelanleihe ausgeben - Unterstützung von Investoren
17.11.2017 - Nordex Aktie: Kursziel heftig gesenkt, dennoch kaufen
17.11.2017 - USU Software muss Prognosen für 2017 senken - Aktie im Minus
17.11.2017 - Agrarius: Gewinnwarnung
17.11.2017 - PNE Wind erhält Millionenkredit von der IKB
17.11.2017 - FinTech Group Aktie: Achtung Kaufsignal, aber…
17.11.2017 - Euroboden: Anleihe gekündigt


Chartanalysen

19.11.2017 - Evotec Aktie: Wichtige Infos für die nächsten Tage
17.11.2017 - FinTech Group Aktie: Achtung Kaufsignal, aber…
17.11.2017 - Geely Aktie: Die nächste Woche könnte spannend werden!
17.11.2017 - BYD Aktie: Mit Sorgen ins Wochenende!
17.11.2017 - Aumann Aktie: Startet jetzt eine Erholungsrallye?
17.11.2017 - Wirecard Aktie: Experten erwarten nächsten Kurssprung!
17.11.2017 - Adva Aktie: Dank Cisco aus dem Keller - und nun?
17.11.2017 - Deutsche Bank Aktie: Sehr deutliche Signale! Jetzt zum Jahreshoch?
17.11.2017 - Evotec Aktie: Der Nebel lichtet sich langsam!
16.11.2017 - Nordex Aktie: Das könnte jetzt was werden!


Analystenschätzungen

17.11.2017 - Infineon Aktie: Kommen gute oder schlechte Nachrichten?
17.11.2017 - SAP Aktie: Sehr optimistischer Ausblick
17.11.2017 - Siemens Aktie: Gelassenheit bei Analysten
17.11.2017 - Deutsche Telekom: Kaufempfehlung bleibt bestehen
17.11.2017 - Zumtobel: Noch mehr schlechte Nachrichten
17.11.2017 - Siemens: Der Zeitpunkt überrascht
17.11.2017 - Lufthansa: Auf Wachstumskurs
17.11.2017 - Gerry Weber: Personalie sorgt für Kursdruck
17.11.2017 - Patrizia Immobilien: Aktie verliert die Kaufempfehlung
17.11.2017 - Wirecard: Dreistelliges Kursziel


Kolumnen

17.11.2017 - Jamaika-Verhandlungen vorerst ohne Durchbruch - National-Bank Kolumne
17.11.2017 - Gute US-Berichtssaison, aber nicht so stark wie im ersten Halbjahr - Commerzbank Kolumne
17.11.2017 - Volkswagen Aktie: Pullback bestätigt mittelfristig intakten Aufwärtstrend - UBS Kolumne
17.11.2017 - DAX: Wichtige 13.000-Punkte-Marke zurückerobert - UBS Kolumne
16.11.2017 - Rentenmarkt erfordert aktives Management - Hansainvest Kolumne
16.11.2017 - Philadelphia Fed Index weiterhin auf hohem Niveau - National-Bank Kolumne
16.11.2017 - Die US-Inflation bleibt im Oktober verhalten - Commerzbank Kolumne
16.11.2017 - SAP Aktie: Der mittelfristige Aufwärtstrend ist intakt - UBS Kolumne
16.11.2017 - DAX: Erholung zum Handelsende sorgt für Entspannung - UBS Kolumne
15.11.2017 - USA: Inflation geht – nur kurzfristig – wieder auf die Marke von 2% zurück - Nord LB Kolumne

Werbung

All Right Reserved by minimalthemes - ©2014 Stoffels & Barck GbR